Affimed Announces Receipt of Nasdaq Delisting Notice
Affimed N.V. (AFMD) has received notice from Nasdaq that its common shares will be delisted from the exchange. Trading of AFMD shares will be suspended on May 20, 2025, following the company's insolvency filing in the Mannheim court, Germany, on May 13, 2025.
The delisting decision is based on three key factors: public interest concerns following the insolvency filing, concerns about existing shareholders' residual equity interest, and doubts about the company's ability to maintain Nasdaq listing requirements. Affimed does not plan to appeal this determination.
Affimed N.V. (AFMD) ha ricevuto comunicazione da Nasdaq riguardo alla rimozione delle sue azioni ordinarie dalla borsa. Il trading delle azioni AFMD sarà sospeso il 20 maggio 2025, a seguito della dichiarazione di insolvenza presentata dalla società presso il tribunale di Mannheim, Germania, il 13 maggio 2025.
La decisione di delisting si basa su tre fattori principali: preoccupazioni di interesse pubblico dopo la dichiarazione di insolvenza, dubbi riguardo all'interesse residuo degli azionisti esistenti e incertezze sulla capacità della società di rispettare i requisiti di quotazione di Nasdaq. Affimed non intende presentare ricorso contro questa decisione.
Affimed N.V. (AFMD) ha recibido notificación de Nasdaq sobre la exclusión de sus acciones comunes de la bolsa. La negociación de las acciones AFMD se suspenderá el 20 de mayo de 2025, tras la presentación de insolvencia de la empresa en el tribunal de Mannheim, Alemania, el 13 de mayo de 2025.
La decisión de exclusión se basa en tres factores clave: preocupaciones de interés público tras la presentación de insolvencia, inquietudes sobre el interés residual de los accionistas existentes y dudas sobre la capacidad de la empresa para cumplir con los requisitos de cotización de Nasdaq. Affimed no planea apelar esta determinación.
Affimed N.V. (AFMD)는 Nasdaq으로부터 보통주가 상장 폐지된다는 통보를 받았습니다. AFMD 주식 거래는 독일 만하임 법원에 2025년 5월 13일에 회사가 파산 신청을 한 후인 2025년 5월 20일에 중단될 예정입니다.
상장 폐지 결정은 파산 신청 후 공공 이익에 대한 우려, 기존 주주들의 잔여 지분에 대한 우려, 그리고 회사가 Nasdaq 상장 요건을 유지할 수 있을지에 대한 의문 등 세 가지 주요 요인에 기반합니다. Affimed는 이 결정에 대해 항소할 계획이 없습니다.
Affimed N.V. (AFMD) a reçu une notification de Nasdaq indiquant que ses actions ordinaires seront retirées de la cote. La négociation des actions AFMD sera suspendue le 20 mai 2025, suite au dépôt de bilan de la société auprès du tribunal de Mannheim, en Allemagne, le 13 mai 2025.
La décision de retrait repose sur trois facteurs principaux : des préoccupations d'intérêt public suite au dépôt de bilan, des inquiétudes concernant les intérêts résiduels des actionnaires existants, et des doutes quant à la capacité de la société à respecter les exigences de cotation de Nasdaq. Affimed ne prévoit pas de faire appel de cette décision.
Affimed N.V. (AFMD) hat von der Nasdaq die Mitteilung erhalten, dass seine Stammaktien von der Börse genommen werden. Der Handel mit AFMD-Aktien wird am 20. Mai 2025 ausgesetzt, nachdem das Unternehmen am 13. Mai 2025 beim Gericht in Mannheim, Deutschland, Insolvenz angemeldet hat.
Die Entscheidung über die Delistung basiert auf drei wesentlichen Faktoren: Bedenken des öffentlichen Interesses nach der Insolvenzanmeldung, Bedenken hinsichtlich der Restkapitalanteile der bestehenden Aktionäre und Zweifel an der Fähigkeit des Unternehmens, die Anforderungen der Nasdaq-Notierung aufrechtzuerhalten. Affimed plant keinen Einspruch gegen diese Entscheidung.
- None.
- Company filed for insolvency in Germany
- Imminent delisting from Nasdaq stock exchange
- Trading suspension of shares effective May 20, 2025
- Company will not appeal the delisting decision
- Concerns about shareholders' residual equity interest
MANNHEIM, Germany, May 14, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice from the staff of the Nasdaq Listing Qualifications Department (the “Staff”) notifying the Company that, in accordance with Nasdaq Listing Rule 5101, 5110(b) and IM-5101-1, the trading of the Company’s common shares will be suspended at the opening of business on May 20, 2025, and a Form 25 Notification of Delisting will be filed with the U.S. Securities Exchange Commission to delist the Company’s securities from The Nasdaq Stock Market (“Nasdaq”).
The Staff’s determination was based on (i) the associated public interest concerns raised by the Company’s announcement that it filed for insolvency in the local court of Mannheim in Germany, (ii) concerns regarding the residual equity interest of the existing listed securities holders and (iii) concerns about the Company’s ability to sustain compliance with all requirements for continued listing on Nasdaq. The Company does not expect to appeal this determination.
As previously reported, on May 13, 2025, the Company filed for insolvency with the local court of Mannheim in Germany.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company’s innate cell engagers (ICE®) enable a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors. ICE® are generated on the Company’s proprietary ROCK® platform which predictably generates customized molecules that leverage the power of innate immune cells to destroy tumor cells. A number of ICE® molecules are in clinical development, being studied as mono- or combination therapy. Headquartered in Mannheim, Germany, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by the bold vision to stop cancer from ever derailing patients’ lives. For more about the Company’s people, pipeline and partners, please visit: www.affimed.com.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. Forward-looking statements include, among other things, statements regarding the listing and trading of the Company’s common shares. Actual results may differ materially from the results anticipated by the Company’s forward-looking statements due to certain risks, uncertainties and other factors described under the heading “Risk Factors” in the Company’s filings with the Securities and Exchange Commission. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.
Investor Relations Contact
Alexander Fudukidis
Director, Investor Relations
E-Mail: a.fudukidis@affimed.com
Tel.: +1 (917) 436-8102
Media Contact
Mary Beth Sandin
Vice President, Marketing and Communications
E-Mail: m.sandin@affimed.com
FAQ
Why is AFMD being delisted from Nasdaq?
When will AFMD stock be suspended from trading on Nasdaq?
Will Affimed appeal the Nasdaq delisting decision?
What happens to AFMD shareholders after the delisting?
When did Affimed file for insolvency?
